| Long noncoding RNAs: emerging players in thyroid cancer pathogenesis |
25 |
| Non-coding RNAs: long non-coding RNAs and microRNAs in endocrine-related cancers |
25 |
| Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial |
24 |
| Genetic testing for indeterminate thyroid cytology: review and meta-analysis |
22 |
| Anaplastic thyroid carcinoma: review of treatment protocols |
20 |
| French Endocrine Society Guidance on endocrine side effects of immunotherapy |
19 |
| Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame |
18 |
| Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study |
17 |
| Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer |
17 |
| Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives |
17 |
| The role of IL-1B in breast cancer bone metastasis |
16 |
| Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis |
16 |
| Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis |
16 |
| Genetics of tumors of the adrenal cortex |
15 |
| Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment |
15 |
| Treatment of refractory thyroid cancer |
14 |
| Exosomes increased angiogenesis in papillary thyroid cancer microenvironment |
14 |
| Immune landscape of papillary thyroid cancer and immunotherapeutic implications |
13 |
| Novel circular RNA circNF1 acts as a molecular sponge, promoting gastric cancer by absorbing miR-16 |
13 |
| Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer |
13 |
| Acquired resistance to aromatase inhibitors: where we stand! |
12 |
| Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms |
12 |
| Role of iodide metabolism in physiology and cancer |
12 |
| The potential role of miRNAs and exosomes in chemotherapy in ovarian cancer |
12 |
| 65 YEARS OF THE DOUBLE HELIX One gene, many endocrine and metabolic syndromes: PTEN-opathies and precision medicine |
12 |
| DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop |
11 |
| Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients |
11 |
| Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia |
11 |
| Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups |
11 |
| TERT aberrancies: a screening tool for malignancy in follicular thyroid tumours |
11 |
| GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling |
11 |
| Role of chemokine receptors in thyroid cancer and immunotherapy |
10 |
| The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines |
10 |
| Aggressive and malignant pituitary tumours: state-of-the-art |
10 |
| TERT structural rearrangements in metastatic pheochromocytomas |
10 |
| Knockdown of BRCA2 enhances cisplatin and cisplatin-induced autophagy in ovarian cancer cells |
10 |
| Neuroendocrine differentiation of prostate cancer leads to PSMA suppression |
10 |
| Proteomics study of serum exosomes from papillary thyroid cancer patients |
10 |
| Analysis of the immune landscape of small bowel neuroendocrine tumors |
10 |
| miR-205 targets angiogenesis and EMT concurrently in anaplastic thyroid carcinoma |
9 |
| Androgen excess in breast cancer development: implications for prevention and treatment |
9 |
| The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance |
9 |
| 65 YEARS OF THE DOUBLE HELIX Genetics informs precision practice in the diagnosis and management of pheochromocytoma |
9 |
| Inflammation and PD-L1 expression in pulmonary neuroendocrine tumors |
9 |
| Oxidative stress in thyroid carcinomas: biological and clinical significance |
9 |
| Clock genes and cancer development in particular in endocrine tissues |
9 |
| PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer |
9 |
| The challenges of modeling hormone receptor-positive breast cancer in mice |
8 |
| Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors |
8 |
| Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): impact on the reclassification of thyroid nodules |
8 |
